Current role
Biotechnology · Healthcare
CEO, Board Member
2025-01-01–present
Tom Frohlich
Board Member
Jade Biosciences, Inc. (JBIO)Equibles does not estimate personal net worth.
Get an email with a short summary when Jade Biosciences, Inc. publishes a filing, an earnings call transcript or a press release.
Get JBIO alertsAbout Tom Frohlich
Tom Frohlich is recorded as Board Member at Jade Biosciences, Inc. (JBIO) since January 1, 2025 and CEO at Jade Biosciences, Inc. (JBIO). The newest filing on record that lists Tom Frohlich as CEO and Board Member at Jade Biosciences, Inc. (JBIO) is dated April 28, 2026. Jade Biosciences, Inc. reported in an 8-K filed May 1, 2025 that Tom Frohlich was appointed Board of Directors, effective April 28, 2025. Jade Biosciences, Inc. reported in an 8-K filed May 1, 2025 that Tom Frohlich was appointed the Company's Chief Executive Officer, effective April 28, 2025. The proxy statement of Jade Biosciences, Inc. reports total compensation of $9,799,759 for Tom Frohlich in fiscal 2025, including a base salary of $621,970. Disclosed compensation is on record for 2 fiscal years. Jade Biosciences, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Jade Biosciences, Inc. includes Eric Dobmeier (Chairman and Board Member), Bradford Dahms (CFO), Benjamin T. Dake (COO) and 7 others.
“On April 28, 2025, the Board decreased its size from seven to six members and appointed the following six individuals to the Board: Eric Dobmeier, Christopher Cain, Tom Frohlich, Tomas Kiselak, Lawrence Klein and Erin Lavelle.”
“On April 28, 2025, the Board appointed Tom Frohlich as the Company's Chief Executive Officer, Jonathan Quick as the Company's Senior Vice President, Finance and Treasurer, Andrew King as the Company's Chief Scientific Officer & Head of Research and Development, Hetal Kocinsky as the Company's Chief Medical Officer and Elizabeth Balta as General Counsel and Corporate Secretary, each to serve at the discretion of the Board.”
Affiliation history
-
Current
2025-01-01–present
Last confirmed April 28, 2026
-
Current
Start not stated–present
Last confirmed April 28, 2026
Company network
Leadership on record at Jade Biosciences, Inc.
- Eric Dobmeier Chairman, Board Member
- Bradford Dahms CFO
- Benjamin T. Dake COO
- Andrew King CTO
- Elizabeth Balta General Counsel
- Christopher Cain Board Member
- Continuing Directors Board Member
- Donald J. Santel Board Member
- Erin Lavelle Board Member
- Habib J. Dable Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Jade Biosciences, Inc. (JBIO) | Chief Executive Officer, President and Director | $621,970 | $9,799,759 |
| 2024 | Jade Biosciences, Inc. (JBIO) | Chief Executive Officer, President and Director | $146,920 | $1,364,396 |